ReviewExperimental & molecular medicine2022
Does SARS-CoV-2 affect neurodegenerative disorders? TLR2, a potential receptor for SARS-CoV-2 in the CNS.
Review in Experimental & molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- SARS-CoV-2 Infection, Vaccination Status, and Dementia Risk: A Nested Case-Control Study.Influenza and other respiratory viruses · 2026Article
- Neurocognitive Impairment After COVID-19: Mechanisms, Phenotypes, and Links to Alzheimer's Disease.Brain sciences · 2025Review
- Need for awareness and surveillance of long-term post-COVID neurodegenerative disorders. A position paper from the neuroCOVID-19 task force of the European Academy of Neurology.Journal of neurology · 2025Review
- Review of organ damage from COVID and Long COVID: a disease with a spectrum of pathology.Medical review (2021) · 2025Review
- Role of toll-like receptors in post-COVID-19 associated neurodegenerative disorders?Frontiers in medicine · 2025Review
- Virus-induced brain pathology and the neuroinflammation-inflammation continuum: the neurochemists view.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Clinical and Immunologic Effects of Paraprobiotics in Long-COVID Patients: A Pilot Study.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Long COVID and its association with neurodegenerative diseases: pathogenesis, neuroimaging, and treatment.Frontiers in neurology · 2024Review
- NLRP3 Inflammasome's Activation in Acute and Chronic Brain Diseases-An Update on Pathogenetic Mechanisms and Therapeutic Perspectives with Respect to Other Inflammasomes.Biomedicines · 2023Review
- Cellular Sensors and Viral Countermeasures: A Molecular Arms Race between Host and SARS-CoV-2.Viruses · 2023Review
- Bioinformatics and systems biology approaches to identify the effects of COVID-19 on neurodegenerative diseases: A review.Medicine · 2022Review
- SARS-CoV-2 Invasion and Pathological Links to Prion Disease.Biomolecules · 2022Article
- Sowing SARS-CoV-2 to reap neurodegeneration: A hamster study.EBioMedicine · 2022Article
- Imaging Techniques: Essential Tools for the Study of SARS-CoV-2 Infection.Frontiers in cellular and infection microbiology · 2022Review
- Post-acute Sequelae of SARS-CoV-2 Infection: A Neglected Public Health Issue.Frontiers in public health · 2022Article
- SARS-CoV-2 Neuroinvasion, Inflammatory Neurodegeneration and Alzheimer's Disease.Frontiers in cellular neuroscience · 2022Article
- microRNA, the Innate-Immune System and SARS-CoV-2.Frontiers in cellular and infection microbiology · 2022Article
- Investigating neurological symptoms of infectious diseases like COVID-19 leading to a deeper understanding of neurodegenerative disorders such as Parkinson's disease.Frontiers in neurology · 2022Review
- SARS-CoV-2, long COVID, prion disease and neurodegeneration.Frontiers in neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The coronavirus (COVID-19) pandemic, caused by severe acute respiratory system coronavirus 2 (SARS-CoV-2), has created significant challenges for scientists seeking to understand the pathogenic mechanisms of SARS-CoV-2 infection and to identify the best therapies for infected patients. Although ACE2 is a known receptor for the virus and has been shown to mediate viral entry into the lungs, accumulating reports highlight the presence of neurological symptoms resulting from infection. As ACE2 expression is low in the central nervous system (CNS), these neurological symptoms are unlikely to be caused by ACE2-virus binding. In this review, we will discuss a proposed interaction between SARS-CoV-2 and Toll-like receptor 2 (TLR2) in the CNS. TLR2 is an innate immune receptor that recognizes exogenous microbial components but has also been shown to interact with multiple viral components, including the envelope (E) protein of SARS-CoV-2. In addition, TLR2 plays an important role in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Based on these observations, we hypothesize that TLR2 may play a critical role in the response to SARS-CoV-2 infiltration in the CNS, thereby resulting in the induction or acceleration of AD and PD pathologies in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.